Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Early TNBC (IMpassion031)
NCT03197935Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2017
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Roche. Started Jul 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03197935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197935.